⌘K
t
On 29 May 2025, Fitch upgraded Hikma Pharmaceuticals PLC's long-term issuer default rating to 'BBB' from 'BBB-' with a stable outlook. Fitch also upgraded the senior unsecured rating on Hikma Finance USA LLC's $500 million notes to 'BBB' from 'BBB-' with a stable outlook.
| Date | 29 May 2025 |
| Time | 07:00:09 |
| Category | Miscellaneous |
| ID | 5768K |
Fitch upgrades Hikma Pharmaceuticals PLC's long-term issuer default rating to 'BBB', outlook stable
London, 29 May 2025 - Hikma Pharmaceuticals PLC (Hikma, Company) is pleased to announce that Fitch has upgraded its long-term issuer default rating and the senior unsecured rating on Hikma Finance USA LLC's $500 million notes to 'BBB' from 'BBB-' with a stable outlook.
Khalid Nabilsi, CFO of Hikma said: "I am pleased that now both Fitch and S&P have upgraded Hikma to BBB, reinforcing our investment grade rating. These upgrades are a strong endorsement of our strategic direction, financial discipline, and operational resilience. They underscore Hikma's solid market position across key geographies and reflect confidence in our ability to consistently deliver strong financial results, supported by our diversified business model, robust balance sheet, and prudent capital allocation."
-- ENDS --
Enquiries:
Hikma (Investors)
|
Susan Ringdal EVP, Strategic Planning and Global Affairs |
+44 (0)20 7399 2760/ +44 (0)7776 477050 |
|
Guy Featherstone Director, Investor Relations |
+44 (0)20 3892 4389/ +44 (0)7795 896738 |
|
Layan Kalisse Senior Associate, Investor Relations |
+44 (0)20 7399 2788/ +44 (0)7970 709912 |
|
FTI Consulting (Media) Ciara Martin |
+44 (0)7779 775979 |
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
©2025 Hikma Pharmaceuticals PLC. All rights reserved.